PCRX
Pacira BioSciences, Inc.Price & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| shares of common stock outstanding | 39.3M | as of March 31, 2026 | -4.4% |
|
|
|||
| shares repurchased | 2.2M | first quarter of 2026 | — |
| covered lives with reimbursement outside of the bundle for EXPAREL | 110M | Q1 2026 call | — |
| IGORD registry OA patients enrolled | 3,500 | Q1 2026 call | — |
| iOVERA sales | 21% | Q1 2026 call | — |
| Orange Book-listed patents protecting EXPAREL | 21 | Q1 2026 call | — |
| ZILRETTA sales | 15% | Q1 2026 call | — |
| Adjusted EBITDA non-GAAP | $186.5M | full-year 2025 | — |
| EXPAREL net product sales | $575.1M | full-year 2025 | — |
| iovera° net product sales | $24.2M | full-year 2025 | — |
| Shares of common stock repurchased | 5.9M | full-year 2025 | — |
| ZILRETTA net product sales | $116.6M | full-year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PCRX
this stock
Pacira BioSciences, Inc.
|
$1.00B | -1.4% | +26.0% | 196.2 | 16.7% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$52.92B | +6.5% | — | — | 0.2% |
|
GALDY
Galderma Group AG/ADR
|
$50.73B | +4.9% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.05B | -4.0% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PCRX | +0.6% | +11.6% | +18.2% | +0.6% | -1.4% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +0.8% | +10.8% | +10.7% | +0.8% | -10.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.